Although RAAS inhibitors slows estimated glomerular filtration rate (eGFR) decline and reduces the relative risk of kidney failure by approximately 20%, substantial residual risk remains [9]
The dosage chart is well-established, tested across thousands of patients in the SURMOUNT trial series , and refined to minimize side effects while maximizing weight loss outcomes
They only mimic what GLP-1 doestemporarilyand come with a long list of side effects like nausea, bloating, digestive issues, and even muscle loss
Pharmacists play a central role in monitoring, counseling on, and facilitating access to GLP-1 RAs, thereby supporting optimal clinical outcomes and therapy tolerability
Rocio Salas Whalen It may surprise you to learn that these medications arent new
An oral GLP-1 drug, Foundayo, is new to the market